SM
BCLI

Sabby Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Sabby Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-203
Closed -$61K – 59
2023
Q3 		$61K Buy
+203
New +$4.62K 0.04% 59
2016
Q2 		– Sell
-12
Closed -$47K – 295
2016
Q1 		$47K Buy
+12
New +$441 ﹤0.01% 282

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Sabby Management's BCLI Position: Q4 2023 in Review

Sabby Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 9,099 shares — an estimated $27.3K sold.

Sabby Management first reported a position in BCLI in Q3 2014 and held it in 23 quarters. The position peaked at $6.27M in Q1 2015. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

  • Sabby Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
  • Sabby Management sold 9,099 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $27.3K.
  • Sabby Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2014 and held it in 23 quarters.
  • Sabby Management's BRAINSTORM CELL THERAPUTC position peaked at $6.27M in Q1 2015.
  • 46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.